Actively Recruiting
Randomized Study Comparing Safety of Flecainide Versus Standard Rhythm-Control Drugs in Adults with Atrial Fibrillation and Stable Coronary Artery Disease
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-10-21
988
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether the antiarrhythmic drug flecainide is as safe as standard rhythm-control drugs sotalol or amiodarone in adults aged 18 years and older who have atrial fibrillation AF with stable coronary artery disease CAD. The study aims to determine if flecainide leads to similar or fewer serious side effects, hospitalizations, or deaths compared to standard treatments. This Phase 4 randomized trial compares these treatments in patients with documented AF and stable CAD. Participants are randomly assigned to receive either flecainide or standard rhythm-control medication sotalol or amiodarone as part of their routine clinical care. Flecainide dosing starts at 100 to 150 mg per day, taken in divided doses or once daily with controlled release, combined with an AV nodal blocker. Sotalol dosing starts at 80 mg twice daily, with adjustments for kidney function, while amiodarone treatment involves a loading phase followed by maintenance dosing. Treatment follows physician preference and patient needs. During the study, participants attend regular hospital visits and telephone follow-ups. They undergo routine heart tests including electrocardiograms and echocardiography, and complete questionnaires about symptoms, quality of life, and daily functioning. Researchers monitor safety outcomes, heart rhythm, healthcare use, and quality of life for at least one year. The main outcome measured is a composite safety outcome after one year of treatment.
CONDITIONS
Brief Title
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
Research Team
J
Joris Ector, MD PhD
B
Bert Vandenberk, MD PhD MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here